The blood-brain barrier is composed of tightly linked endothelial cells that limit the passage of pathogens and specific types of small and large molecules from the blood into the brain. This critical protective function also restricts the diffusion of therapeutics into the brain representing a major challenge to the development of new medicines for CNS diseases.

By combining the highly specialized enzymatic activity and brain-focused tissue distribution profile of fatty-acid amide hydrolase (FAAH), amplified with novel peripherally restricted FAAH inhibitors, our prodrug and peripheral restriction technology enables us to precisely tailor CNS and peripheral drug exposure.

Optimizing central versus peripheral exposure of active molecules enables us to match biodistribution with disease pathophysiology, providing Autobahn with a range of opportunities to leverage our platform to develop new therapeutics addressing unmet human health needs.